Skip to main content

Boston Scientific Value Stock - Dividend - Research Selection

Boston scientific

ISIN: US1011371077 , WKN: 884113

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy systems, wires, and stents to treat venous diseases; and peripheral embolization devices, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; devices to diagnose, treat, and palliate pulmonary diseases within the airway and lungs; and products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson\'s disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Back on the Radar: Prior Picks Offer Fresh Opportunity

2026-02-18
Periods of volatility often create the most compelling opportunities to revisit prior ideas with fresh perspective. This week I focus on opportunities within communication services, healthcare, and consumer staples. Netflix was covered by George Glover last December.

How Investors May Respond To Boston Scientific (BSX) EP Momentum And CHAMPION‑AF Data Overhang

2026-02-18
Boston Scientific recently reported fourth-quarter 2025 sales of US$5,286 million and net income of US$672 million, alongside 2026 guidance calling for double‑digit reported and organic net sales growth. At the same time, the company is facing heightened attention on its electrophysiology and atrial fibrillation portfolio, with new clinical trials such as OPTION‑EMEA and upcoming CHAMPION‑AF data potentially influencing how investors view its long-term growth mix. We’ll now explore how...

Disposable Endoscope Analysis Report 2025: A $4.95 Billion Market by 2029 - Aging Population and Growing Healthcare Expenditure Accelerate Shift Toward Disposable Endoscopic Solutions

2026-02-17
The global disposable endoscope market, valued at US$1.89 billion in 2023, is projected to reach US$4.95 billion by 2029, driven by rising hospital-acquired infections and demand for safer diagnostic tools. These sterile, single-use endoscopes reduce infection risks, catering to the GI, bronchoscopic, urologic, and arthroscopic applications. The market is set for a CAGR of 17%, with North America leading in 2023, and Asia Pacific poised for rapid growth. Key players like Boston Scientific and Ol

Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $109

2026-02-17
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $112 to $109.

J&J's MedTech Shows Strong Growth in 2025: Will 2026 be Better?

2026-02-16
JNJ's MedTech unit grows in 2025 on cardiovascular strength; with new launches, can 2026 bring faster growth?

Peering Into Boston Scientific Corp's Recent Short Interest

2026-02-16

3 S&P 500 Stocks Worth Investigating

2026-02-16
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.

Boston Scientific Corporation (BSX) Maintains Analyst Ratings Amid Target Adjustments

2026-02-15
Boston Scientific Corporation (NYSE:BSX) is one of the best medical technology stocks to invest in. On February 6, RBC Capital lowered its price target on Boston Scientific Corporation (NYSE:BSX) to $115 from $130 and maintained an Outperform rating on the shares. RBC made the move in response to Boston Scientific’s Q4 2025 earnings share on […]

Boston Scientific Stock Slide Tests Support As Outlook And Value Diverge

2026-02-14
Boston Scientific (NYSE: BSX) shares have fallen sharply in recent weeks, taking the stock back to technical support levels not seen for over a year. The pullback has coincided with reported institutional selling, even as the company reports solid operating performance. Management has expressed confidence in continuing to grow faster than the broader market, highlighting a gap between investor sentiment and the company outlook. For you as an investor, the tension between price action and...

Reassessing Boston Scientific (BSX) After A 30% Pullback In The Share Price

2026-02-14
If you are wondering whether Boston Scientific is attractively priced or looking stretched at around US$74.73 per share, you are not alone. Many investors are reassessing what they are really paying for here. The stock recently closed at US$74.73, with returns of a 2.0% decline over 7 days, 20.3% decline over 30 days, 21.1% decline year to date, and 29.6% decline over 1 year, set against gains of 60.6% over 3 years and 96.5% over 5 years. Recent news has focused on Boston Scientific's...